ATE96844T1 - Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression. - Google Patents

Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression.

Info

Publication number
ATE96844T1
ATE96844T1 AT89105110T AT89105110T ATE96844T1 AT E96844 T1 ATE96844 T1 AT E96844T1 AT 89105110 T AT89105110 T AT 89105110T AT 89105110 T AT89105110 T AT 89105110T AT E96844 T1 ATE96844 T1 AT E96844T1
Authority
AT
Austria
Prior art keywords
angiogenin
proteins
mutant
activity
angiogenic
Prior art date
Application number
AT89105110T
Other languages
English (en)
Inventor
Jeffrey W Harper
Bert L Vallee
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE96844T1 publication Critical patent/ATE96844T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89105110T 1988-03-28 1989-03-22 Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression. ATE96844T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/173,760 US4900673A (en) 1988-03-28 1988-03-28 Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
EP89105110A EP0335243B1 (de) 1988-03-28 1989-03-22 Menschliches mutantes Angiogenin (Angiogenese-Faktor mit überlegener Angiogenin-Aktivität), Gene dafür und Methode zur Expression

Publications (1)

Publication Number Publication Date
ATE96844T1 true ATE96844T1 (de) 1993-11-15

Family

ID=22633370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89105110T ATE96844T1 (de) 1988-03-28 1989-03-22 Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression.

Country Status (13)

Country Link
US (1) US4900673A (de)
EP (1) EP0335243B1 (de)
JP (1) JPH03503641A (de)
KR (1) KR900700609A (de)
AT (1) ATE96844T1 (de)
AU (1) AU621358B2 (de)
CA (1) CA1331356C (de)
DE (1) DE68910354T2 (de)
DK (1) DK233390A (de)
IE (1) IE890954L (de)
PT (1) PT90129A (de)
WO (1) WO1989009277A1 (de)
ZA (1) ZA892270B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520914A (en) * 1987-08-06 1996-05-28 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
IL96519A0 (en) * 1990-02-15 1991-08-16 Harvard College Covalent angiogenin/rnase hybrids
DE4309391C2 (de) * 1993-03-23 1996-10-24 Harald Prof Dr Tschesche Verwendung von Angiogenin und/oder dessen Fragmenten als Wirkstoff zur Verhinderung oder Begrenzung der Sekretion von Proteinen aus Leukozyten
WO2000015792A2 (en) * 1998-09-14 2000-03-23 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2001019987A1 (en) * 1999-09-13 2001-03-22 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
EP0888086B1 (de) 1996-02-15 2005-07-27 Biosense Webster, Inc. Sonde zur exkavation
US6443974B1 (en) * 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
WO2001040464A1 (en) * 1999-11-30 2001-06-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
US5852001A (en) * 1996-12-23 1998-12-22 The Endowment For Research In Human Biology Method and compounds for inhibition of ribonucleases
WO2000053752A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
ES2293473T3 (es) 1998-02-05 2008-03-16 Biosense Webster, Inc. Administracion intracardiaca de farmaco.
US6211157B1 (en) 1998-05-01 2001-04-03 Sulzer Biologics, Inc. Protein mixtures to induce therapeutic angiogenesis
US7087577B2 (en) 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
ATE458050T1 (de) * 1998-12-01 2010-03-15 Genentech Inc Promotion oder inhibition von angiogenese und kardiovaskularisation
CA2503475A1 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU768694B2 (en) * 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US6743600B1 (en) 1999-04-30 2004-06-01 Monsanto Technologies Llc Method of removing N-terminal alanine residues from polypeptides with Aeromonas aminopeptidase
US6794159B1 (en) * 1999-04-30 2004-09-21 Pharmacia Corporation Method of removing n-terminal alanine residues from polypeptides with aeromonas aminopeptidase
AU5441200A (en) * 1999-06-02 2000-12-18 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
CA2412211A1 (en) * 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
WO2004106491A2 (en) * 2003-05-22 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Angiogenin-based hiv-1 therapies
GB0425625D0 (en) 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US7601689B2 (en) 2007-04-12 2009-10-13 Naidu Lp Angiogenin complexes (ANGex) and uses thereof
US8828698B2 (en) * 2007-04-12 2014-09-09 Naidu Lp Immobilized angiogenin mixtures and uses thereof
US20130136727A1 (en) * 2009-11-19 2013-05-30 President And Fellows Of Harvard College Angiogenin and Variants Thereof for Treatment of Neurodegenerative Diseases
CN115947818A (zh) * 2022-10-25 2023-04-11 福州大学 一种血管生成素1突变体的设计及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721672A (en) * 1985-08-28 1988-01-26 President And Fellows Of Harvard College CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression
IL80944A (en) * 1985-12-17 1994-10-07 Synergen Inc Boulder Colo U S A factor in the formation of blood vessels in a human placenta capable of inducing protease synthesis in the inner lining of capillary cells, DNA synthesis. And migration of materials
FR2623509B1 (fr) * 1987-11-19 1990-04-20 Centre Nat Rech Scient Proteine de 17 kd a action angiogenique, son procede d'isolement a partir de lait de mammiferes, compositions therapeutiques la contenant, procede de detection et/ou de dosage et reactifs immunologiques de detection et de dosage des angiogenines de mammiferes, de leurs homologues et de leurs fragments

Also Published As

Publication number Publication date
EP0335243B1 (de) 1993-11-03
DK233390D0 (da) 1990-09-27
DK233390A (da) 1990-11-26
AU621358B2 (en) 1992-03-12
KR900700609A (ko) 1990-08-16
WO1989009277A1 (en) 1989-10-05
JPH03503641A (ja) 1991-08-15
DE68910354D1 (de) 1993-12-09
PT90129A (pt) 1989-11-10
ZA892270B (en) 1991-12-24
AU3433189A (en) 1989-10-16
IE890954L (en) 1989-09-28
DE68910354T2 (de) 1994-03-03
EP0335243A2 (de) 1989-10-04
EP0335243A3 (en) 1989-11-23
US4900673A (en) 1990-02-13
CA1331356C (en) 1994-08-09

Similar Documents

Publication Publication Date Title
ATE96844T1 (de) Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression.
ES2091768T3 (es) Factor neurotrofico ciliar purificado.
EP0155188A3 (en) Alpha-1-antitrypsin mutants and dna coding therefor and the production of each, and therapeutic formulations using such mutants and their preparation
ATE117375T1 (de) Transduktionsveränderte fibroblasten und ihre anwendung.
EP0375724A4 (en) Biologically active bactericidal/permeability-increasing protein fragments
DE3680368D1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
ATE123060T1 (de) Tgf-beta induziertes gen und protein.
CA2066204A1 (en) Cystic fibrosis gene
ATE121776T1 (de) Expression des biologisch aktiven faktors xiii.
ATE167701T1 (de) Human-nervenwachstumsfaktor
DK91389D0 (da) Kallikreiner, deres fremstilling og laegemidler indeholdende polypeptiderne
DE69117123D1 (de) Menschliches MK Gen und Protein-Sequenz
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
DK587488A (da) Fibroblast-vaekstfaktor, nucleotidsekvens kodende derfor, praeparat indeholdende faktoren og fremgangsmaade til fremstilling deraf
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE230025T1 (de) Proteinanaloge des ldl-rezeptors und deren kodierende gene
HUT62327A (en) Process for producing somatotropins modified in their alfa-helix 1 region and their combination with other mutants
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
BR1100940A (pt) Polipeptìdeos puros, sequências adn, molécula adn recombinada, célula hospedeira, processo de manipulação genética para produção de polipeptìdeo, e, uso de um polipeptìdeo
DE3878296D1 (de) Rekombinante menschliche glutathionperoxidase, verfahren zur herstellung des enzyms und dafuer kodierende dna.
ZA887950B (en) Human t-pa(u-pa)substitution-mutant proteins,recombinant dna coding therefor,transfected host cells,preparation of the mutant proteins,and pharmaceutical compositions
ATE75485T1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties